| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.951 | 0.001 | 0.951 | Hemostatic | 0.951 0.001 DBMET03244 0.951 0.001 DBMET03245 | ||
| 0.901 | 0.001 | 0.901 | Guanylate cyclase stimulant | 0.901 0.001 DBMET03244 0.901 0.001 DBMET03245 | ||
| 0.774 | 0.001 | 0.774 | Guanylate cyclase 1 stimulant | 0.774 0.001 DBMET03244 0.774 0.001 DBMET03245 | ||
| 0.71 | 0.005 | 0.71 | Cardiotonic | 0.71 0.005 DBMET03244 0.71 0.005 DBMET03245 | ||
| 0.499 | 0.032 | 0.499 | Toll-Like receptor 7 agonist | 0.499 0.032 DBMET03244 0.499 0.032 DBMET03245 | ||
| 0.497 | 0.032 | 0.497 | Toll-Like receptor agonist | 0.497 0.032 DBMET03244 0.497 0.032 DBMET03245 | ||
| 0.347 | 0.015 | 0.347 | RET inhibitor | 0.347 0.015 DBMET03244 0.347 0.015 DBMET03245 | ||
| 0.315 | 0.023 | 0.315 | TRKC antagonist | 0.315 0.023 DBMET03244 0.315 0.023 DBMET03245 | ||
| 0.322 | 0.039 | 0.322 | Tyrosine kinase inhibitor | 0.322 0.039 DBMET03244 0.322 0.039 DBMET03245 | ||
| 0.245 | 0.04 | 0.245 | Anticoagulant | 0.245 0.04 DBMET03244 0.245 0.04 DBMET03245 | ||
| 0.227 | 0.032 | 0.227 | Tyrosine-protein kinase receptor antagonist | 0.227 0.032 DBMET03244 0.227 0.032 DBMET03245 | ||
| 0.247 | 0.059 | 0.247 | EphB2 antagonist | 0.247 0.059 DBMET03244 0.247 0.059 DBMET03245 | ||
| 0.225 | 0.041 | 0.225 | Thrombolytic | 0.225 0.041 DBMET03244 0.225 0.041 DBMET03245 | ||
| 0.193 | 0.03 | 0.193 | Protein-tyrosine kinase (PTK, not ETK, WZC) inhibitor | 0.193 0.03 DBMET03244 0.193 0.03 DBMET03245 | ||
| 0.193 | 0.03 | 0.193 | Abl kinase inhibitor | 0.193 0.03 DBMET03244 0.193 0.03 DBMET03245 | ||
| 0.162 | 0.01 | 0.162 | Proto-oncogene tyrosine-protein kinase c-hck inhibitor | 0.162 0.01 DBMET03244 0.162 0.01 DBMET03245 | ||
| 0.267 | 0.118 | 0.267 | Vasodilator, coronary | 0.267 0.118 DBMET03244 0.267 0.118 DBMET03245 | ||
| 0.235 | 0.086 | 0.235 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.235 0.086 DBMET03244 0.235 0.086 DBMET03245 | ||
| 0.173 | 0.027 | 0.173 | Proto-oncogene tyrosine-protein kinase Kit inhibitor | 0.173 0.027 DBMET03244 0.173 0.027 DBMET03245 | ||
| 0.176 | 0.033 | 0.176 | TRKB antagonist | 0.176 0.033 DBMET03244 0.176 0.033 DBMET03245 | ||
| 0.153 | 0.01 | 0.153 | Phosphatidylinositol 3-kinase delta inhibitor | 0.153 0.01 DBMET03244 0.153 0.01 DBMET03245 | ||
| 0.166 | 0.025 | 0.166 | Platelet activating factor alpha antagonist | 0.166 0.025 DBMET03244 0.166 0.025 DBMET03245 | ||
| 0.151 | 0.014 | 0.151 | Raf kinase C inhibitor | 0.151 0.014 DBMET03244 0.151 0.014 DBMET03245 | ||
| 0.223 | 0.087 | 0.223 | Vasodilator | 0.223 0.087 DBMET03244 0.223 0.087 DBMET03245 | ||
| 0.135 | 0.017 | 0.135 | mTOR complex 1 inhibitor | 0.135 0.017 DBMET03244 0.135 0.017 DBMET03245 | ||
| 0.128 | 0.02 | 0.128 | Adenosine A2 receptor antagonist | 0.128 0.02 DBMET03244 0.128 0.02 DBMET03245 | ||
| 0.121 | 0.016 | 0.121 | Phosphatidylinositol kinase inhibitor | 0.121 0.016 DBMET03244 0.121 0.016 DBMET03245 | ||
| 0.154 | 0.053 | 0.154 | c-Src kinase inhibitor | 0.154 0.053 DBMET03244 0.154 0.053 DBMET03245 | ||
| 0.129 | 0.03 | 0.129 | Hepatocyte growth factor antagonist | 0.129 0.03 DBMET03244 0.129 0.03 DBMET03245 | ||
| 0.305 | 0.211 | 0.305 | Antiinflammatory | 0.305 0.211 DBMET03244 0.305 0.211 DBMET03245 | ||
| 0.148 | 0.057 | 0.148 | Toll-Like receptor antagonist | 0.148 0.057 DBMET03244 0.148 0.057 DBMET03245 | ||
| 0.112 | 0.022 | 0.112 | Adenosine A2a receptor antagonist | 0.112 0.022 DBMET03244 0.112 0.022 DBMET03245 | ||
| 0.111 | 0.023 | 0.111 | mTOR complex 2 inhibitor | 0.111 0.023 DBMET03244 0.111 0.023 DBMET03245 | ||
| 0.18 | 0.095 | 0.18 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.18 0.095 DBMET03244 0.18 0.095 DBMET03245 | ||
| 0.167 | 0.083 | 0.167 | LIM domain kinase 1 inhibitor | 0.167 0.083 DBMET03244 0.167 0.083 DBMET03245 | ||
| 0.114 | 0.031 | 0.114 | Janus tyrosine kinase 2 inhibitor | 0.114 0.031 DBMET03244 0.114 0.031 DBMET03245 | ||
| 0.143 | 0.063 | 0.143 | Phosphodiesterase inhibitor | 0.143 0.063 DBMET03244 0.143 0.063 DBMET03245 | ||
| 0.219 | 0.143 | 0.219 | Immunomodulator | 0.219 0.143 DBMET03244 0.219 0.143 DBMET03245 | ||
| 0.102 | 0.026 | 0.102 | Phosphodiesterase 5A inhibitor | 0.102 0.026 DBMET03244 0.102 0.026 DBMET03245 | ||
| 0.104 | 0.031 | 0.104 | Janus tyrosine kinase 3 inhibitor | 0.104 0.031 DBMET03244 0.104 0.031 DBMET03245 | ||
| 0.096 | 0.03 | 0.096 | Phosphodiesterase V inhibitor | 0.096 0.03 DBMET03244 0.096 0.03 DBMET03245 | ||
| 0.11 | 0.045 | 0.11 | Protein kinase (Mos, Mil/Raf, MEKK, RIPK, TESK, LIMK, IRAK, ILK, Activin/TGF-beta) inhibitor | 0.11 0.045 DBMET03244 0.11 0.045 DBMET03245 | ||
| 0.081 | 0.02 | 0.081 | Phosphatidylinositol 3-kinase gamma inhibitor | 0.081 0.02 DBMET03244 0.081 0.02 DBMET03245 | ||
| 0.135 | 0.074 | 0.135 | Protein-tyrosine kinase Lyn inhibitor | 0.135 0.074 DBMET03244 0.135 0.074 DBMET03245 | ||
| 0.146 | 0.086 | 0.146 | Src kinase inhibitor | 0.146 0.086 DBMET03244 0.146 0.086 DBMET03245 | ||
| 0.085 | 0.028 | 0.085 | Phosphodiesterase VIII inhibitor | 0.085 0.028 DBMET03244 0.085 0.028 DBMET03245 | ||
| 0.076 | 0.023 | 0.076 | Phosphatidylinositol 3-kinase alpha inhibitor | 0.076 0.023 DBMET03244 0.076 0.023 DBMET03245 | ||
| 0.079 | 0.029 | 0.079 | Janus tyrosine kinase 1 inhibitor | 0.079 0.029 DBMET03244 0.079 0.029 DBMET03245 | ||
| 0.096 | 0.048 | 0.096 | Phosphodiesterase IV inhibitor | 0.096 0.048 DBMET03244 0.096 0.048 DBMET03245 | ||
| 0.093 | 0.047 | 0.093 | TIE antagonist | 0.093 0.047 DBMET03244 0.093 0.047 DBMET03245 | ||
| 0.091 | 0.046 | 0.091 | TIE-2 antagonist | 0.091 0.046 DBMET03244 0.091 0.046 DBMET03245 | ||
| 0.055 | 0.015 | 0.055 | Factor XIa inhibitor | 0.055 0.015 DBMET03244 0.055 0.015 DBMET03245 | ||
| 0.117 | 0.076 | 0.117 | Protein kinase (CK1) delta inhibitor | 0.117 0.076 DBMET03244 0.117 0.076 DBMET03245 | ||
| 0.05 | 0.01 | 0.05 | Factor XI inhibitor | 0.05 0.01 DBMET03244 0.05 0.01 DBMET03245 | ||
| 0.126 | 0.092 | 0.126 | Aurora-C kinase inhibitor | 0.126 0.092 DBMET03244 0.126 0.092 DBMET03245 | ||
| 0.078 | 0.046 | 0.078 | Raf kinase inhibitor | 0.078 0.046 DBMET03244 0.078 0.046 DBMET03245 | ||
| 0.062 | 0.032 | 0.062 | Bruton tyrosine kinase inhibitor | 0.062 0.032 DBMET03244 0.062 0.032 DBMET03245 | ||
| 0.097 | 0.068 | 0.097 | Cyclin-dependent kinase 1 inhibitor | 0.097 0.068 DBMET03244 0.097 0.068 DBMET03245 | ||
| 0.105 | 0.076 | 0.105 | Interleukin 2 antagonist | 0.105 0.076 DBMET03244 0.105 0.076 DBMET03245 | ||
| 0.073 | 0.044 | 0.073 | Toll-Like receptor 7 antagonist | 0.073 0.044 DBMET03244 0.073 0.044 DBMET03245 | ||
| 0.065 | 0.037 | 0.065 | Raf kinase B inhibitor | 0.065 0.037 DBMET03244 0.065 0.037 DBMET03245 | ||
| 0.114 | 0.087 | 0.114 | Proto-oncogene tyrosine-protein kinase Yes inhibitor | 0.114 0.087 DBMET03244 0.114 0.087 DBMET03245 | ||
| 0.096 | 0.07 | 0.096 | Aurora-A kinase inhibitor | 0.096 0.07 DBMET03244 0.096 0.07 DBMET03245 | ||
| 0.082 | 0.058 | 0.082 | Transforming growth factor beta 3 antagonist | 0.082 0.058 DBMET03244 0.082 0.058 DBMET03245 | ||
| 0.056 | 0.032 | 0.056 | mTOR inhibitor | 0.056 0.032 DBMET03244 0.056 0.032 DBMET03245 | ||
| 0.081 | 0.06 | 0.081 | AXL receptor tyrosine kinase inhibitor | 0.081 0.06 DBMET03244 0.081 0.06 DBMET03245 | ||
| 0.031 | 0.013 | 0.031 | HCV NS5A inhibitor | 0.031 0.013 DBMET03244 0.031 0.013 DBMET03245 | ||
| 0.064 | 0.045 | 0.064 | Tyk2 inhibitor | 0.064 0.045 DBMET03244 0.064 0.045 DBMET03245 | ||
| 0.06 | 0.042 | 0.06 | Potassium channel (Ca-activated) blocker | 0.06 0.042 DBMET03244 0.06 0.042 DBMET03245 | ||
| 0.049 | 0.034 | 0.049 | Phosphatidylinositol 3-kinase beta inhibitor | 0.049 0.034 DBMET03244 0.049 0.034 DBMET03245 | ||
| 0.094 | 0.085 | 0.094 | Glycogen synthase kinase-3 beta inhibitor | 0.094 0.085 DBMET03244 0.094 0.085 DBMET03245 | ||
| 0.092 | 0.086 | 0.092 | Platelet activating factor antagonist | 0.092 0.086 DBMET03244 0.092 0.086 DBMET03245 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |